Predictive Technology Group (PRED) Appoints John C. Nelson, M.D., M.P.H. to the Predictive Technology Group Scientific Advisory Board
January 11, 2018 09:30 ET
|
PREDICTIVE TECHNOLOGY GROUP, INC.
SALT LAKE CITY, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group...
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
April 07, 2015 20:25 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 7, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the...
Boardroom Radio Interview with Mesoblast Chief Executive
February 02, 2014 20:06 ET
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...
MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR
April 22, 2013 04:07 ET
|
Mesoblast
Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...